Fora Capital, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Fora Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$143.31 - $247.0 $1.03 Million - $1.77 Million	7,173 New	7,173 $1.74 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $258,154 - $335,151	1,705 New	1,705 $326,000
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $1.22 Million - $2.04 Million	8,774 New	8,774 $1.76 Million
Q4 2021 Feb 11, 2022	SELL	$159.56 - $209.29 $355,659 - $466,507	-2,229 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $73,841 - $90,362	-435 Reduced 16.33%	2,229 $421,000
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $342,670 - $471,234	2,664 New	2,664 $452 Million
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $851,480 - $1.16 Million	-7,026 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$104.21 - $156.44 $732,179 - $1.1 Million	7,026 New	7,026 $1.04 Billion
Q1 2020 May 15, 2020	SELL	$93.12 - $133.99 $980,460 - $1.41 Million	-10,529 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$74.51 - $124.23 $784,515 - $1.31 Million	10,529 New	10,529 $1.21 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Fora Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Fora Capital, LLC with notifications on news.